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Abstract
 
Mature dendritic cells (DCs) are powerful antigen presenting cells that have the unique capac-
ity to migrate to the T cell zone of draining lymph nodes after subcutaneous injection. Here we
report that treatment of antigen-pulsed mature DCs with tumor necrosis factor (TNF)-related
activation-induced cytokine (TRANCE), a TNF family member, before immunization en-
hances their adjuvant capacity and elicits improved T cell priming in vivo, such that both pri-
mary and memory T cell immune responses are enhanced. By enumerating migratory DCs in
the draining lymph nodes and by studying their function in stimulating naive T cells, we show
that one of the underlying mechanisms for enhanced T cell responses is an increase in the num-
ber of ex vivo antigen-pulsed DCs that are found in the T cell areas of lymph nodes. These re-
sults suggest that the longevity and abundance of mature DCs at the site of T cell priming influ-
ence the strength of the DC-initiated T cell immunity in situ. Our findings have the potential
to improve DC-based immunotherapy; i.e., the active immunization of humans with autolo-
gous DCs that have been pulsed with clinically significant antigens ex vivo.
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Introduction
 
Dendritic cells (DCs)
 
1
 
 are antigen-presenting cells special-
ized to initiate T cell immunity, and as such can be re-
garded as nature’s adjuvant (1, 2). DCs have the capacity in
vivo to migrate from tissues, where they encounter anti-
gens, to the T cell areas of lymphoid tissues, where im-
mune responses begin (2–5). DCs reside in tissues as imma-
ture cells, specialized to capture and process antigens, and,
after antigen capture, they mature in response to inflamma-
tory stimuli characterized by an upregulation of MHC and
T cell costimulatory molecules (2). DCs then migrate to
the draining LN and stimulate antigen-specific T cells to
initiate an immune response. However, several reports sug-
gest that the life span of DCs in the LN is short. Although
DCs migrate to the LNs via afferent lymphatics, they are
not found in the efferent lymph (6, 7). It is difficult to
identify DCs in the LN 
 
.
 
2 d after subcutaneous injection
(4, 5). In tissue culture, fully differentiated or mature DCs
undergo rapid apoptosis, but this can be delayed substan-
tially by treatment with several members of the TNF fam-
ily, including CD40 ligand (CD40L), TNF-related activa-
tion-induced cytokine (TRANCE), and TNF (8).
TRANCE, a recently described member of the TNF
family (9), is a regulator of the immune system and of bone
development (for a review, see reference 10). TRANCE is
expressed on activated T cells (11), and a major target for
TRANCE in the immune system appears to be mature
DCs that express a high level of TRANCE receptor
(TRANCE-R) (8, 12). In vitro, TRANCE promotes the
survival of mature DCs, most likely by upregulating the ex-
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pression of Bcl-X
 
L
 
 (8), and induces the production of pro-
inflammatory cytokines, such as IL-1 and IL-6, and cyto-
kines that stimulate and induce differentiation of T cells,
such as IL-12 and IL-15 (11, 13). Therefore, TRANCE is
likely to act as a positive feedback regulator during produc-
tive T cell–DC interactions (10).
In this study, we have treated antigen-pulsed mature DCs
with soluble TRANCE, injected the cells subcutaneously,
and then evaluated their numbers and function in LNs. We
have found that TRANCE treatment greatly enhances the
number and persistence of antigen-presenting DCs in the
draining LNs, and increases the ensuing primary and mem-
ory T cell responses. Thus, our results indicate that the lon-
gevity and abundance of antigen-pulsed DCs are critical fac-
tors in the magnitude of a T cell response to antigen in vivo,
and provide a potential avenue to improve the efficacy of
DC-based immunotherapy in humans.
 
Materials and Methods
 
Dendritic Cells.
 
DCs were generated from bone marrow pro-
genitors, using GM-CSF as described (14, 15). On day 6 of cul-
ture, the immature DCs were pulsed for 6 h with 10 
 
m
 
g/ml puri-
fied protein derivative (PPD) from 
 
Mycobacterium tuberculosis
 
 (Statens
Serum Institute) or OVA (Sigma Chemical Co.) in complete me-
dium (RPMI 1640 supplemented with 5% FCS, 50 
 
m
 
M 2-ME,
and 20 
 
m
 
g/ml gentamicin). The cells were then dislodged and
transferred to fresh 100-mm culture dishes at 10
 
6
 
/ml to allow DC
maturation. On day 7, the mature DCs were pulsed overnight
with recombinant, soluble TRANCE (1 
 
m
 
g/ml) (8). On day 8,
the DCs were washed twice in HBSS and resuspended in HBSS
for injection into the footpads of mice (5 
 
3 
 
10
 
5
 
 cells per footpad).
 
Proliferation Assays for T Cell Priming and Cytokine Production.
 
Draining LNs (popliteal LNs), cervical LNs, and spleen were har-
vested from different groups of mice (C57BL/6 or BALB/c;
Taconic Farms), and single cell suspensions were prepared. Cells
were restimulated in vitro with 10-fold serial dilutions of PPD
(0.1–10 
 
m
 
g/ml) or OVA, for 3 d in triplicate in flat-bottomed 96-
well plates at 3 
 
3 
 
10
 
5
 
 LN cells/well in 200 
 
m
 
l of Click’s medium
(GIBCO BRL) supplemented with 0.5% normal mouse serum,
 
l
 
-glutamine, penicillin-streptomycin, Hepes, and 2-ME. [
 
3
 
H]thymi-
dine was added for the last 8 h of culture, and thymidine incorpo-
ration was measured using standard scintillation procedures. For
cytokine production, cells prepared as described above were cul-
tured at 3 
 
3 
 
10
 
6
 
/ml in complete Click’s medium in the presence
of 10 
 
m
 
g/ml of PPD or OVA for 48 h. Supernatants were then as-
sessed for IFN-
 
g
 
 and IL-4 by ELISA (R&D Systems).
 
Presentation of Antigens by DCs That Have Migrated to LNs.
 
LN
DCs were purified using CD11c-MACS beads (Miltenyi Biotec) af-
ter digestion in 400 U/ml collagenase following the manufacturer’s
instructions. DO11-10 CD4
 
1
 
 T cells were purified from LNs of
DO11-10 TCR transgenic mice (provided by Dr. Dennis Loh) us-
ing CD4 magnetic beads (Miltenyi Biotec). 5 
 
3 
 
10
 
4
 
 DO11-10
CD4
 
1
 
 T cells were cultured in RPMI 1640 supplemented with
10% FCS, 2-ME, 
 
l
 
-glutamine, penicillin-streptomycin, with vari-
ous numbers of CD11c
 
1
 
 cells in round-bottomed 96-well plates for
4 d and pulsed with [
 
3
 
H]thymidine during the last 8 h of culture.
 
Measurement of Delayed-Type Hypersensitivity.
 
4.5 or 9 wk af-
ter priming with antigen-pulsed DCs in the left hind footpad,
mice were challenged by the injection of 30 
 
m
 
g PPD in PBS in
the right hind footpad, and PBS only in the left footpad. Footpad
swelling was measured after 24 and 48 h and recorded as the dif-
ference between right and left footpad thickness.
 
Labeling and Migration of DCs.
 
To follow the migration of bone
marrow–derived DCs in draining LNs after footpad injection, cells
were labeled before injection with 5-chloromethyl-fluorescein diac-
etate (CMFDA) or 5-(and 6)-(((4-chloromethyl)benzoyl)amino)tet-
ramethylrhodamine (CMTMR) according to the manufacturer’s
protocol (Molecular Probes). DCs were incubated for 30 min at
37
 
8
 
C in 10 
 
m
 
M CMFDA or CMTMR in serum-free RPMI, and
then another 30 min at 37
 
8
 
C in serum-free RPMI. The DCs were
washed, counted, and injected in both hind footpads (5 
 
3 
 
10
 
5
 
 per
footpad). For confocal microscopy, the draining popliteal LNs were
harvested at various time points after injection, processed, and ana-
lyzed by confocal microscopy as described previously (5). For
FACS
 
®
 
 analysis, popliteal LNs were harvested, then digested with
400 U/ml collagenase (Sigma Chemical Co.) for 30 min at 37
 
8
 
C in
RPMI, 1% FCS. EDTA at a final concentration of 10 mM was
added during the last 5 min. Total LN cells were counted and then
stained with PE-conjugated anti-CD11c mAb (PharMingen). After
gating on live cells, 10
 
6
 
 events were acquired to quantify the abso-
lute number of migrating DCs per LN (CD11c
 
1
 
 and FL1
 
high
 
).
 
Results
 
Enhancement of Antigen-specific Primary Th Cell Responses
by TRANCE-treated DCs.
 
To determine whether the pre-
treatment of antigen-pulsed mature DCs ex vivo with TNF
family members such as TRANCE would enhance the ad-
juvant effect of DCs in vivo, we used the PPD from myco-
bacteria, a classical antigen for T cell–mediated immunity
and an antigen known to be presented by DCs in mice
(14). DCs were prepared from bone marrow progenitors
stimulated with GM-CSF (14, 15). PPD was added for 6 h
on day 6 of the cultures, when most of the DCs were in an
immature state. These immature DCs display efficient en-
docytic activity (14) and sequester most of their antigen-
presenting MHC class II products within intracellular en-
docytic compartments (MIICs [16]), but lack strong cell
surface expression of CD40, TRANCE-R, and CD86
(10). After the 6-h exposure to low doses of PPD, DC
maturation was induced by transfer to a new culture vessel
as described (14, 15). We confirmed that the DCs began to
express high levels of CD40, TRANCE-R, and CD86
upon maturation (10). The mature DCs were then treated
with or without soluble TRANCE during the last 12 h of
the culture, washed, and injected subcutaneously in the
hind footpads of naive mice. Aliquots of each DC prepara-
tion were further cultured in vitro to test whether a brief
exposure to TRANCE was sufficient to increase DC sur-
vival. A brief exposure of mature DCs to TRANCE was
indeed sufficient to enhance DC survival in vitro (Fig. 1
A), suggesting that cellular responses induced by TRANCE
responsible for antiapoptotic effects on mature DCs are ini-
tiated at an early point after TRANCE stimulation (8).
The immunogenicity of the subcutaneously injected
DCs was then assessed after in vitro restimulation and mea-
surement of antigen-specific T cell proliferation and cyto-
kine production. PPD-specific proliferative responses by T
cells from draining popliteal LNs were induced when mice
were immunized with PPD-pulsed DCs (Fig. 1 B), but not 
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with PPD alone (data not shown), confirming that DCs act
as adjuvants (3). The PPD-specific T cell responses from mice
immunized with TRANCE-treated, PPD-pulsed DCs were
much higher than those from mice immunized with PPD-
pulsed DCs without prior treatment of TRANCE. Ap-
proximately 20-fold more PPD was required to show a
similar level of proliferation by draining LN T cells from
mice immunized with DCs that were PPD-pulsed without
treatment with TRANCE (Fig. 1 B). In controls, the LN
cells did not respond to a nonspecific protein, OVA (Fig. 1,
B and C). Primed popliteal LN cells from mice immunized
with PPD-pulsed DCs also showed strong cytokine pro-
duction (IFN-
 
g 
 
and IL-4) upon rechallenge with PPD (Fig.
1 C). Immunization with TRANCE-treated, PPD-pulsed
DCs also increased the production of IFN-
 
g 
 
by severalfold,
but the production of IL-4 was not affected (Fig. 1 C).
No priming was found in LNs that were distal to the site of
DC injection, namely mesenteric and axillary LNs, whether
DCs were treated with TRANCE or not (data not shown).
However, when spleen cells were examined at a later time
point (day 10), a small but significant response to PPD was
noted (data not shown), suggesting a migration of primed T
cells from the popliteal LNs to the spleen. Furthermore, this
response was significantly higher in spleen cells from mice in-
jected with TRANCE-treated, PPD-pulsed DCs compared
with that from mice immunized with DCs that were PPD-
pulsed without TRANCE treatment (data not shown). Simi-
lar results were also obtained when OVA was used as antigen
(data not shown). Therefore, these results indicate that
TRANCE-treated, antigen-pulsed DCs have an increased
capacity to induce CD4
 
1
 
 T cell priming in vivo.
 
Enhancement of Antigen-specific Memory Responses by
TRANCE-treated DCs.
 
The effects of DCs on the estab-
lishment of memory was then tested using the induction of
delayed-type hypersensitivity (DTH) as a criterion. When
mice were immunized with PPD-pulsed DCs, no signifi-
cant DTH was observed 4.5 wk later (Fig. 2). However,
when mice were immunized with DCs that had been pulsed
with PPD and exposed to TRANCE, DTH responses
were evident 4.5 and 9 wk later (Fig. 2). Taken together,
these results indicate that TRANCE treatment enhances
the capacity of antigen-pulsed DCs to induce both primary
and secondary immune responses in vivo.
 
TRANCE Increases the Number of DCs in Draining LNs.
 
Prior results (8), confirmed repeatedly during the course of
these experiments, had shown that TRANCE did not alter
the expression of several cell surface molecules that contribute
Figure 1. TRANCE enhances the capacity of DCs to act as adjuvants for
T cell priming. (A) Antigen-pulsed mature DCs were treated with 1 mg/ml
soluble TRANCE for 12 h, washed three times, and cultured for 2 d to
determine the effect of TRANCE treatment on DC viability. The results
represent the mean 6 SD. (B) Immature bone marrow–derived DCs
were pulsed for 6 h with (filled symbols) or without (open symbols) 10
mg/ml PPD. The cells were dislodged and transferred to new 100-mm
culture dishes for 48 h to allow maturation. During the last 12 h, the cells
were pulsed with 1 mg/ml soluble TRANCE (circles) or with medium
alone (squares). The DCs were then extensively washed, and 2 3 105 cells
were injected in the left hind footpad of anesthetized naive mice. 7 d
later, draining popliteal LN cells were prepared and cultured for 3 d at 3 3
105 cells/well in 200 ml of complete Click’s medium supplemented with
0.5% normal mouse serum in flat-bottomed 96-well plates in the presence
of various concentrations of PPD. Proliferation was assessed during the
last 8 h of culture by pulsing the cells with 0.5 mCi [3H]thymidine. Each
point represents the mean 6 SD of three mice per group at each time
point. Results from one experiment representative of five are shown. (C)
As in B, but supernatants of the LN cultures with the highest antigen
concentration were harvested after 48 h to measure IFN-g (left) and IL-4
(right) production by ELISA. Results of one experiment representative of
three are shown. The results represent the mean 6 SD.
Figure 2. Induction of T cell memory by TRANCE-treated antigen-
pulsed DCs. Mice were injected in the left hind footpad with 2 3 105
DCs that were either unpulsed, TRANCE treated, PPD pulsed, or both
PPD pulsed and TRANCE treated as in the legend to Fig. 1. 4.5 or 9 wk
later, mice were challenged by the injection of 30 mg of PPD in the right
hind footpad and PBS only in the left. Footpad swelling was assessed 24 h
later. Each bar represents the increase in thickness of right versus left foot-
pad (mean 6 SD, 9–12 mice per group). *P , 0.05, compared with the
group of mice injected with PPD-pulsed DCs. 
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to the T cell stimulatory function of mature DCs, including
MHC class II and costimulatory molecules such as B7-1
(CD80), B7-2 (CD86), intercellular adhesion molecule 1
(ICAM-1 [CD54]), and CD40. Therefore, we looked for
other mechanisms whereby TRANCE might act to enhance
the capacity of DCs as an adjuvant. As mentioned above,
DCs die shortly after reaching the LN (5). Given the ca-
pacity of TRANCE to enhance DC survival in vitro (Fig.
1 A), we tested whether TRANCE treatment could en-
hance the longevity of DCs in the draining LNs. OVA-
pulsed DCs were labeled with a fluorescent vital dye
(CMTMR) before subcutaneous injection. Draining LNs
were subsequently collected and analyzed by confocal mi-
croscopy as described previously (5). Whether DCs were
pretreated with TRANCE or not, all of the subcutaneously
injected DCs were found almost exclusively in the paracorti-
cal regions of the LN (Fig. 3 A), previously shown to be the
site for antigen-specific T cell–DC interactions (5). However,
when DCs were pretreated with TRANCE, there were con-
siderably higher numbers of DCs detected in the draining
LNs (Fig. 3, A and B).
To further quantitate the increase in the number of
TRANCE-treated DCs in the draining LNs, mice were in-
jected subcutaneously with CMFDA-labeled DCs, and the
draining LNs were then collected 1–5 d later. The LNs
were dissociated by collagenase treatment, which has been
shown to release most of the DCs from the T cell areas
(17). All of the fluorescent cells were found to express
CD11c (Fig. 3 C), a marker that is expressed at high levels
on DCs, but not on lymphocytes and macrophages (18, 19).
As described previously (15), the bone marrow–derived
DCs that migrated to the LNs expressed lower levels of
CD11c than resident LN DCs (Fig. 3 C). Only a small
number of fluorescent DCs were found in the LNs (Fig. 3
C), indicating that most of the DCs injected subcutane-
ously must have died rapidly in situ since it is known that
most of those DCs leave the injection site (4). Neverthe-
less, the number of labeled DCs in draining LNs was mark-
edly increased (up to 5–10-fold) when the DCs were
treated before injection with TRANCE (Fig. 3 D). More-
over, the number of injected DCs remained at increased
levels for at least 5 d, whereas few injected DCs were ob-
Figure 3. TRANCE treatment enhances numbers of
injected mature DCs in the LN draining the site of in-
jection. OVA-pulsed mature DCs were treated with or
without TRANCE, labeled with CMTMR or CMFDA,
and 5 3 105 cells were injected subcutaneously in both
hind footpads of anesthetized naive mice. For A and B,
CMTMR-labeled DCs were injected, and draining
popliteal LNs were harvested at various time points af-
ter subcutaneous injection, processed, and the sections
were analyzed by confocal immunofluorescent micros-
copy as described (reference 5). (A) Images were taken
from the paracortical region of the LNs of mice injected
3 d earlier with DCs with or without TRANCE. The
optical thickness of each section is 4 mm. (B) The num-
ber of DCs was quantitated per unit area (mm2) of LN.
The results represent the mean 6 SD of two to three
mice per group derived from a single experiment. Sim-
ilar results were obtained in three other independent
experiments. (C and D) CMFDA-labeled DCs were injected, and the draining popliteal LNs were harvested daily and digested with collagenase. The LN
cells were counted, stained with PE-conjugated CD11c, and analyzed on a FACScan™. (C) FACS® data showing that the injected DCs are recovered as
a small fraction (#1%) of the CD11c1 subset (arrow). (D) The absolute number of injected DCs in each draining LN (CD11c1 and FL-1high) was cal-
culated. Each point represents the mean 6 SD of three mice in each group and at each time point. Similar results were obtained in three other indepen-
dent experiments. 
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served after 3 d when the DCs were not pretreated with
TRANCE (Fig. 3 D).
We then determined whether DCs found in draining LNs
3 d after subcutaneous injection retained their capacity to
present antigen and stimulate T cells. Immature bone mar-
row–derived DCs were pulsed with OVA, and then treated
with TRANCE as described above. 5 
 
3 
 
10
 
5
 
 cells were then
injected in each footpad of BALB/c mice, and draining LNs
were harvested 3 d later and digested with collagenase.
CD11c
 
1
 
 cells were then purified and used to stimulate resting
CD4
 
1
 
 T cells from DO11-10 TCR transgenic mice (20). As
shown in Fig. 4, CD11c
 
1
 
 cells from mice injected with
TRANCE-treated, OVA-pulsed DCs induced significantly
higher proliferative responses for DO11-10 CD4
 
1
 
 T cells
than those from mice immunized with DCs pulsed with
OVA only (Fig. 4): approximately three- to fivefold more
CD11c
 
1
 
 cells from mice immunized with OVA-pulsed DCs
were required to obtain a similar T cell proliferative response
than from mice immunized with TRANCE-treated, OVA-
pulsed DCs. Since we consistently observed a three- to five-
fold difference in the number of injected DCs in the draining
LNs 3 d after immunization (Fig. 3), the results suggest that
the difference in the number of antigen-pulsed DCs found in
the LN is responsible for differential T cell proliferation.
 
Discussion
 
Mature DCs are powerful antigen-presenting cells thought
to be short-lived both in vitro and in vivo (2). The short
half-life of these cells could represent an important mecha-
nism for controlling the normal immune response and for
ensuring adequate space for the constant influx of fresh DCs
loaded with different antigens. However, it is not known
whether an increase in DC survival, and therefore in the
longevity of antigen-pulsed DCs at the site of T cell priming
in LNs, would affect the strength of an immune response.
In this study, we have shown that treatment of DCs with
TRANCE before immunization enhances their adjuvant ca-
pacity, which results in better T cell priming in vivo. Al-
though DCs without prior TRANCE treatment were able to
prime Th cells in the draining LNs, as assessed by antigen-
specific proliferation assay and cytokine production, this pri-
mary response was strongly enhanced when DCs were pre-
treated with TRANCE before subcutaneous injection.
Moreover, a significant memory response was observed only
in mice injected with TRANCE-treated DCs. How does
TRANCE produce these consequences? One possibility
would be that TRANCE enhances the adjuvant property of
DCs via cytokine induction. We have recently shown that
TRANCE induced multiple cytokines in DCs, including
IL-1, IL-6, IL-12, and IL-15 (11, 13). Since IL-12 and IL-15
are important cytokines involved in the activation and differ-
entiation of T cells (21, 22), this effect may contribute to the
increased T cell responses we observed with TRANCE-
pulsed DCs. IL-12 production might also explain the substan-
tial increase in IFN-
 
g
 
 priming and Th1 response (22) found in
draining LNs of mice injected with TRANCE-pulsed DCs.
However, it is also possible that one of the underlying
mechanisms for the enhanced T cell immune responses by
TRANCE is an increase in the number of antigen-pulsed
DCs that are found in the draining LNs. Similar to its effect
on DC survival in vitro, TRANCE may have increased the
survival of DCs at the site of injection, which would possi-
bly increase the number of DCs migrating out of this site
and into the draining LN. TRANCE may also enhance the
survival of DCs that have migrated to the T cell area. Ingulli
et al. (5) have shown that 24 h after subcutaneous injection,
peptide-pulsed mature DCs are found in the draining LN
and they interact with antigen-specific T cells. Since acti-
vated T cells express CD40L and TRANCE, which can
increase the survival of DCs in situ, it is possible that the
antiapoptotic molecules induced by TRANCE (8) before
the subcutaneous injection may have protected antigen-
presenting mature DCs against spontaneous apoptosis until
they are able to fully communicate with antigen-specific T
cells. In addition, TRANCE might modify the expression
of those chemokine receptors, such as CCR7 (23, 24), that
favor the entry of DCs into afferent lymphatics and homing
to the T cell areas. Although several of these mechanisms
may operate together, we favor the theory that the effect of
TRANCE is on DC numbers as opposed to “function per
cell,” because the efficacy of T cell stimulation by DCs iso-
lated from the draining LNs is proportional to the number
of surviving migrated DCs (Fig. 4).
Our results now suggest that the strength of DC–T cell
interaction required for successful activation of antigen-
specific T cells (25) can be influenced not only by the cyto-
kine secretion profile of DCs, but also by their longevity
and/or abundance at the site of T cell priming. Therefore,
future experiments should determine whether the longev-
ity and/or abundance of antigen-presenting DCs at the site
of T cell priming are critical factors for the induction of T
cell responses to antigens delivered by natural routes, e.g.,
viral infection or tumors.
Figure 4. Increased presenta-
tion of antigens by DCs from the
draining LNs of mice immu-
nized with TRANCE-treated
DCs. Immature bone marrow–
derived DCs were pulsed for 6 h
with or without 10 mg/ml OVA.
The cells were dislodged and
transferred to new 100-mm cul-
ture dishes for 48 h to allow
maturation. During the last 12 h,
the cells were pulsed with 1 mg/
ml soluble TRANCE (black
bars) or with medium alone (white
bars). The DCs were then
washed, and 5 3 105 cells were
injected in hind and front footpads of anesthetized naive mice. 3 d later,
draining LNs were harvested, digested in collagenase, and DCs were pu-
rified using CD11c-MACS beads following the manufacturer’s instruc-
tions (Miltenyi Biotec). Serial dilutions of purified CD11c1 DCs were
mixed with 5 3 104 DO11-10 TCR transgenic resting CD41 T cells in
round-bottomed 96-well plates for 72 h. Proliferation was assessed during
the last 8 h of culture. Background proliferation obtained with CD11c1
DCs prepared in a similar way from BALB/c mice immunized with
TRANCE-treated DCs without OVA was subtracted. 
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Although this report focuses on the effects of TRANCE
on DCs, CD40L can also enhance the survival and adju-
vanticity of DCs (our unpublished data). This observation
may explain previous reports that CD40L enhances DC
function in vivo, allowing them to stimulate CD8
 
1 T cells
and induce CTL differentiation (26–29). However, while the
expression of CD40L is restricted to CD41 T cells, TRANCE
is also expressed on activated CD81 T cells, and may there-
fore confer the ability to enhance DC survival and function
on CD81 T cells as well (11). Since TNF family members
are rapidly upregulated on T cells by TCR stimulation (11),
our results suggest that activated T cells provide a powerful
positive reinforcement to antigen-presenting DCs by en-
hancing their survival and cytokine production.
DC-mediated immunotherapy (i.e., the active immuni-
zation of humans with autologous DCs that have been
pulsed with clinically significant antigens, including tumor,
viral, and bacterial antigens [30, 31]) may be improved by
the application of our findings. Initial studies in humans
have shown that the subcutaneous injection of DCs pulsed
ex vivo with protein antigen or peptide is an efficient way
to prime and boost CD41 and CD81 T cells (32). However,
recent reports suggest that current protocols result in very
low rates of survival and/or migration of DCs in the drain-
ing LNs (33), indicating that the methodology is operating
far below the adjuvant potential of DCs. We have also
found that, despite a significant adjuvant effect, mature bone
marrow–derived DCs migrated poorly to draining LN after
subcutaneous injection. Exposure of DCs to TNF family
members such as TRANCE or CD40L before injection is
likely to improve the efficacy of DC-based immunotherapy
by enhancing the in vivo survival and the number of anti-
gen-presenting cells in draining LNs. This hypothesis is
currently under investigation.
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